Drug · CHEMBL490
PAROXETINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PAROXETINE. Drugs and targets, record CHEMBL490. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL490
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- (-)3s,4r-paroxetine, Arketis, Arotin, BRL 29060, BRL-29060, Besitram, Casbol, Daparox, Fg-7051, Frosinor, Motivan, Parogen, Paroxetina, Paxpar, Xetanor
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | Serotonin transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6532 |
Source ChEMBL
Diseases34
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 34Source Open Targets
See all 34 diseasesTrials195
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01360866 | Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | Phase 3 | 2,944 | 2018-09-17 | paroxetine | Its name | ClinicalTrials.gov |
| NCT00666757 | A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression | Phase 4 | 750 | 2010-06-15 | paroxetine | Its name | ClinicalTrials.gov |
| NCT04597190 | Sequenced Treatment Effectiveness for Posttraumatic Stress | Phase 4 | 700 | 2025-03-26 | paroxetine | Its name | ClinicalTrials.gov |
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | 635 | 2021-07-02 | paroxetine | Its name | ClinicalTrials.gov | |
| NCT00866294 | Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study) | Phase 3 | 416 | 2010-11-15 | paroxetine | Its name | ClinicalTrials.gov |
| NCT02932904 | Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers | Phase 4 | 361 | 2018-09-14 | paroxetine | Its name | ClinicalTrials.gov |
| NCT00677352 | A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder | Phase 4 | 321 | 2011-05-06 | paroxetine | Its name | ClinicalTrials.gov |
| NCT00074802 | Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder | Phase 3 | 150 | 2017-06-14 | paroxetine | Its name | ClinicalTrials.gov |
| NCT00292370 | Quetiapine Augmentation for Treatment-resistant PTSD | Phase 4 | 124 | 2014-07-01 | paroxetine | Its name | ClinicalTrials.gov |
| NCT00086190 | Study of Antidepressants in Parkinson's Disease | Phase 3 | 115 | 2013-01-04 | paroxetine | Its name | ClinicalTrials.gov |
1 to 10 of 195
See all 195 trialsComparisons in its trials18
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Sertraline vs Paroxetine: serious adverse events | 2 of 157 | 1 of 162 | 319 | NCT00677352 | Trial comparisons |
| During 4 Weeks of Paroxetine vs During 4 Weeks of Placebo: serious adverse events | 0 of 62 | 0 of 62 | 124 | NCT00218439 | Trial comparisons |
| Paroxetine vs Bupropion: serious adverse events | 3 of 36 | 2 of 38 | 74 | NCT00429169 | Trial comparisons |
| Treatment (Paroxetine) Group vs Combat Exposed Controls: serious adverse events | 0 of 36 | 0 of 29 | 65 | NCT00700999 | Trial comparisons |
| Paroxetine Continuation vs Paroxetine With CBT Augmentation: deaths from any cause | 0 of 29 | 0 of 32 | 61 | NCT00074802 | Trial comparisons |
| Paroxetine Continuation vs Paroxetine With CBT Augmentation: serious adverse events | 1 of 29 | 0 of 32 | 61 | NCT00074802 | Trial comparisons |
| Paroxetine vs Placebo: serious adverse events | 0 of 29 | 0 of 27 | 56 | NCT00812812 | Trial comparisons |
| Vilazodone; Viibryd vs Paroxetine; Paxil: serious adverse events | 0 of 26 | 0 of 30 | 56 | NCT01608295 | Trial comparisons |
1 to 10 of 18
See all 18 comparisons in its trialsPapers from its trials156
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials13
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Choice Reaction Time | 2 | 0 | ConductCognition |
| Monetary Incentive Delay | 2 | 2 | ConductCognition |
| Symbol Coding | 2 | 1 | ConductCognition |
| Trail Making Test A | 2 | 0 | ConductCognition |
| Trail Making Test B | 2 | 0 | ConductCognition |
| Card Sorting Test (Berg) | 1 | 0 | ConductCognition |
| Complex Figure Copy and Recall | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Emotion Regulation Task | 1 | 1 | ConductCognition |
| Go/No-Go Task | 1 | 1 | ConductCognition |
1 to 10 of 13
See all 13 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL490
GET https://conductscience.org/api/drugs/v1/CHEMBL490/diseases?page=2